Literature DB >> 49055

Two antigenically distinct species of human interferon.

E A Havell, B Berman, C A Ogburn, K Berg, K Paucker, J Vilcek.   

Abstract

Rabbit antisera prepared against interferon produced in human fibroblast cell cultures stimulated with poly(1).poly(C) neutralized the activity of interferon preparations produced in various human fibroblast cultures timulated either with poly(1)poly)C) or with viruses. However, these antisera showed no detectable neutralizing activity against interferon produced in cultures of human leukocytes. On the other hand, most rabbit antisera against the human leukocyte interferon were active in neutralizing both homologous interferon and fibroblast interferons. A preparation of antiserum against leukocyte interferon, active against both leukocyte and fibroblast interferons, was shown by affinity chromatography to have two distinct antibody populations, one of which was specific for the fibroblast interferon. We conclude that the heterologous neutralizing activity of sera from rabbits immunized with leukocyte interferon is liekly to be due to the presence of two antigenic species of interferon. The major antigenic species of leukocyte interferon preparations (designated "Le") is distinct from huamn fibroblast interferon. The minor species of leukocyte interferon ("F") is either identical with, or closely related to, interferon produced in human fibroblast cultures.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 49055      PMCID: PMC432721          DOI: 10.1073/pnas.72.6.2185

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  12 in total

1.  Suppression of human interferon production by inhibitors of glycosylation.

Authors:  E A Havell; J Vilcek; E Falcoff; B Berman
Journal:  Virology       Date:  1975-02       Impact factor: 3.616

2.  Affinity chromatography of human leukocyte and diploid cell interferons on sepharose-bound antibodies.

Authors:  K Berg; C A Ogburn; K Paucker; K E Mogensen; K Cantell
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

3.  Production of Sendai virus for cell fusion.

Authors:  R E Giles; F H Ruddle
Journal:  In Vitro       Date:  1973 Sep-Oct

4.  Studies on virus-induced interferons produced by the human amniotic membrane and white blood cells.

Authors:  P Duc-Goiran; B Galliot; C Chany
Journal:  Arch Gesamte Virusforsch       Date:  1971

5.  Immunology of interferons. I. Immune response to protective and nonprotective interferons.

Authors:  R E Levy-Koenig; M J Mundy; K Paucker
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

6.  Further studies on the production of interferon by human leukocyte in vitro.

Authors:  H Strander; K Cantell
Journal:  Ann Med Exp Biol Fenn       Date:  1967

7.  Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines.

Authors:  G Henle; W Henle
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

8.  Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination.

Authors:  L B Epstein; D A Stevens; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

9.  Partial purification of human interferon by affinity chromatography.

Authors:  C B Anfinsen; S Bose; L Corley; D Gurari-Rotman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

10.  Antiviral effect of interferon covalently bound to sepharose.

Authors:  H Ankel; C Chany; B Galliot; M J Chevalier; M Robert
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

View more
  52 in total

1.  In vitro properties of a Listeria monocytogenes bacteriophage-resistant mutant predict its efficacy as a live oral vaccine strain.

Authors:  Patricia A Spears; M Mitsu Suyemoto; Terri S Hamrick; Rebecca L Wolf; Edward A Havell; Paul E Orndorff
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon.

Authors:  W R Fleischmann; J A Georgiades; L C Osborne; H M Johnson
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

3.  Cell-free synthesis of human interferon.

Authors:  S Pestka; J McInnes; E A Havell; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

4.  Production by mixed lymphocyte cultures of a type II interferon able to protect macrophages against virus infection.

Authors:  J L Virelizier; A C Allison; E de Maeyer
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

5.  Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage.

Authors:  W E Stewart; L S Lin; M Wiranowska-Stewart; K Cantell
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

6.  Differential expression of human interferon genes.

Authors:  J Hiscott; K Cantell; C Weissmann
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

7.  Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis.

Authors:  P A Neighbour; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

8.  The role of interferon beta in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells.

Authors:  D D Sedmak; S Chaiwiriyakul; D A Knight; W J Waldmann
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.

Authors:  L T May; D C Helfgott; P B Sehgal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  Multiple active sites on human interferons.

Authors:  K Paucker; B J Dalton; C A Ogburn; E Törmä
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.